Stock Market Reviews

BFRI (Biofrontera Inc.) News

Get the latest news, insights, and market updates on BFRI (Biofrontera Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
  Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG.New earnout structure reduces payment rate to 12%–15% of U.S. net sales from 25%–35%.Closing releases final $2.5 million of $11 million financing led by existing investors Rosalind Advisors and AIGH Capital Management, which is expected to fund Biofrontera Inc. to profitability. WOBURN, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera I
  Oct 23, 2025 - $BFRI
• Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven?
  We feel now is a pretty good time to analyse Biofrontera Inc.'s ( NASDAQ:BFRI ) business as it appears the company may...
  Sep 28, 2025 - $BFRI
• Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
  Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 1:15 p.m. ET
  Sep 26, 2025 - $BFRI
• Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
  WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program. For more than 20 years, Lytham Partners has been one of the country's leading investor relations firms, having created one of the industry's largest and most diverse
  Sep 23, 2025 - $BFRI
• Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk
  All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental New Drug Application (sNDA) planned for submission in Q2 2026 WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercial
  Sep 16, 2025 - $BFRI
• Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
  Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of phot
  Aug 25, 2025 - $BFRI
• Biofrontera Inc (BFRI) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Operational ...
  Biofrontera Inc (BFRI) reports significant sales growth and strategic advancements despite increased expenses and net loss in Q2 2025.
  Aug 15, 2025 - $BFRI
• Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
  Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update. Highlights from the first six months of 2025 included the following: Total revenues for the second quarter of 2025 were $9.0 million, a 15% increase from the same period
  Aug 13, 2025 - $BFRI
• Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
  Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company’s commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthen
  Aug 11, 2025 - $BFRI
• Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
  Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 7, 2025 - $BFRI